viewInnovaDerma PLC

InnovaDerma PLC - Directorate Change

RNS Number : 2374G
InnovaDerma PLC
24 November 2020

 LEI: 213800WRAP6W8VDL6B38

InnovaDerma PLC

("InnovaDerma" or the "Group")

Directorate Changes

InnovaDerma (LSE: IDP), a developer of beauty, personal care and life science products, is pleased to announce that Simon Pyper, subject to  shareholder approval, will become a Non-Executive Director at the conclusion of the Company's General Meeting on 16 December 2020. Rodney Turner who has been a Non-executive Director of the Group since September 2014 has chosen not to stand for re-election and will be stepping down from the Board from the beginning of the General Meeting.  Simon, upon appointment will also become a member of the Nominations and Remuneration Committees and chair the Audit Committee thereby replacing Rodney's membership role in those committees.

Simon has strong experience as an executive director of public companies and brings with him digital and marketing expertise. He was formerly Chief Executive Officer and Chief Financial Officer of digital marketing group Be Heard Group plc. Simon was appointed Chief Financial Officer of Be Heard Group plc in May 2018 and undertook the role of CEO from September 2018. Prior to this, he was Chief Financial Officer of AIM listed GlobalData plc from 2007 to 2017. During his tenure, Simon oversaw its reverse takeover of TMN plc and admission to AIM and facilitated its acquisition led growth strategy. Simon is currently the Chief Financial Officer of Xenia Broking, one of the largest credit insurance brokers in the UK.

Joe Bayer, Executive Chairman said:

"We are very pleased to have Simon join our board and believe that his extensive public company experience, coupled with his digital marketing and retail expertise, will further enhance the board's skills and growth prospects for the Group.


"I would also like to take this opportunity to express our heartfelt thanks to Rodney for his exemplary service to InnovaDerma.  Over the last six years, he has provided considerable insight, regulatory and corporate governance expertise and wise counsel from the very early beginnings and through the growth of the Group to its current listed status.  On behalf of the Board, we wish him the best for the future."


Simon John Pyper said:

 "InnovaDerma is an exciting business and one which has proven to be resilient in very challenging times. I look forward to joining the Board and working with my fellow directors to support its future growth." 


The Company confirms there is no further information to be disclosed under the requirements of Listing Rule 9.6.13R in relation to Simon John Pyper's appointment.



Further enquiries



Joe Bayer

Blake Hughes



+61 417 870 743

c/o TB Cardew


finnCap Ltd

Geoff Nash/Kate Bannatyne

Alice Lane - Corporate Broking


+44 (0)207 220 0500


TB Cardew

Shan Shan Willenbrock/Tom Allison

Olivia Rosser


+ 44 (0)7775 848537

+ 44 (0)20 7930 0777




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

Quick facts: InnovaDerma PLC

Price: -

Market: LSE
Market Cap: -

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Capital Network's analyst Ed Stacey on Innovaderma's strong growth drivers...

Analyst Ed Stacey talks investors through InnovaDerma (LON:IDP) reported results on 21 February for the first half of the full year (FY) to June 2019. Results were in line with January's trading statement, with first half (H1) revenues down 7.5% driven by disruptions to the direct-to-consumer...

on 26/2/19

4 min read